Document Detail

Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability.
MedLine Citation:
PMID:  11724449     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Autonomic dysfunction is frequently observed in patients with multiple sclerosis (MS) but the evolution over time and the relationship to clinical characteristics are not yet established. OBJECTIVES: We investigated the correlation of disease activity and progression of disability with composite scores of cardiovascular autonomic dysfunction and serum levels of catecholamines in a cross-sectional study of patients with clinically active and clinically stable MS. In a longitudinal study of clinically active MS patients, we performed cardiovascular reflex tests for up to 2 years. METHODS: Twenty-six patients with clinically active relapsing-remitting MS, age 33.0 +/- 7.3 years, and nine patients with clinically stable MS, age 41.3 +/- 10.9 were studied. Twenty-four healthy volunteers served as controls. Standard autonomic tests were repeated at 3, 6, 12, 18 and 24 months in 18 of the 26 active patients participating in a placebo-controlled trial with interferon-beta-1a. Parasympathetic dysfunction was assessed by heart rate response to the Valsalva manoeuvre, deep breathing and active change of posture, while sympathetic dysfunction was analysed by blood pressure response to active change of posture and to sustained handgrip, and by measuring levels of norepinephrine and epinephrine in serum obtained in the supine position. RESULTS: In the cross-sectional study, the number of patients with at least one abnormal sympathetic test was higher in the 'active' patient group (39%) than in healthy controls (8%, P< 0.02) or 'stable' patients (0%, P< 0.04), while no difference was seen in the parasympathetic score. Median catecholamine levels were significantly lower in 'active' MS patients than in those with stable disease (norepinephrine, 204 ng/l (interquartile range 158-310 ng/l) vs 363 ng/l (269-507 ng/l), P<0.02 and epinephrine, 23 ng/l (16-28 ng/l) vs 32 ng/l (24-107 ng/l), P<0.04). In the subgroup of patients studied longitudinally, parasympathetic but not sympathetic dysfunction increased slightly during the follow-up period, with a significant correlation to the increase in clinical disability (r=0.7, P<0.002). No difference was seen for any of the autonomic scores between patients treated with interferon-beta (n=12) and those receiving placebo (n=6). During acute exacerbations, only parasympathetic dysfunction tended to increase in parallel with a deterioration in the EDSS. CONCLUSIONS: Parasympathetic dysfunction was closely related to the progression of disability in patients with MS. In contrast, sympathetic dysfunction was associated to the clinical activity of MS. This is in line with previous observations suggesting that the autonomic nervous system may be intimately linked with the disordered immune regulation in MS.
P Flachenecker; K Reiners; M Krauser; A Wolf; K V Toyka
Related Documents :
20811489 - Prevalence, detection, and management of the metabolic syndrome in patients with acute ...
2614429 - Changes within the "normal" cerebral white matter of multiple sclerosis patients during...
21330679 - Febuxostat for treatment of chronic gout.
6746319 - Gluten antibodies in patients with multiple sclerosis.
16564129 - Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction.
16477479 - Neuropsychology of multiple sclerosis--an overview.
2142489 - Improved results with surgical treatment of renovascular hypertension: an individualize...
3966399 - Positive exercise thallium-201 test responses in patients with less than 50% maximal co...
21991169 - Sperm quality changes in survivors of severe burns.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  7     ISSN:  1352-4585     ISO Abbreviation:  Mult. Scler.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-11-28     Completed Date:  2002-05-01     Revised Date:  2006-03-03    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  327-34     Citation Subset:  IM    
Department of Neurology, Julius-Maximilians-Universität Würzburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / administration & dosage
Autonomic Nervous System Diseases / etiology*,  physiopathology*
Catecholamines / blood
Cross-Sectional Studies
Disability Evaluation
Disease Progression
Interferon-beta / administration & dosage
Longitudinal Studies
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / complications*,  drug therapy,  physiopathology*
Parasympathetic Nervous System / physiopathology
Sympathetic Nervous System / physiopathology
Vagus Nerve / physiopathology
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Catecholamines; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta
Comment In:
Mult Scler. 2003 Mar;9(2):216; author reply 215   [PMID:  12708819 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardiovascular autonomic dysregulation and fatigue in multiple sclerosis.
Next Document:  Differential treatment effect on measures of neurologic exam, functional impairment and patient self...